Estimation of plasma esterolytic activity and its in vitro inhibition by proteinase inhibitors during acute pancreatitis in the human.
The plasma esterolytic activity was measured using benzyol arginine ethyl ester (BAEe) in the peripheral venous blood of patients with acute pancreatitis, normal healthy volunteers and a contrast group of patients with acute intrabdominal inflammations other than acute pancreatitis. The plasma esterolytic activity was significantly elevated in the pancreatitis group. This activity was maximal during the first 48 hours of the illness and remained elevated for a further 8 days thereafter. Aprotinin in a dose of 2000 K.I. u/0-3 ml plasma did not completely inhibit this esterolytic activity, although it resulted in a more substantial inhibition than either ovomucoid or soy bean inhibitor. It is concluded that pancreatic enzymes are released into the circulation during acute pancreatitis and that Aprotinin does not completely inhibit this proteolytic activity. This polyvalent proteinase inhibitor should therefore be administered in much higher dosage than that used hitherto in  acute pancreatitis. The plasma esterolytic activity seems to be of diagnostic value in acute  pancreatitis.
D000208:Acute Disease; D000368:Aged; D000681:Amylases / Q000097:blood; D007611:Aprotinin / Q000494:pharmacology*; D001120:Arginine; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010059:Ovomucin / Q000494:pharmacology; D010195:Pancreatitis / Q000201:enzymology*; D010447:Peptide Hydrolases / Q000097:blood*; D011480:Protease Inhibitors
D011480:Protease Inhibitors; D010059:Ovomucin; D007611:Aprotinin; D001120:Arginine; D000681:Amylases; D010447:Peptide Hydrolases